Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 179

Results For "IT"

10301 News Found

American Cancer Society and Pfizer announce a US $15 million initiative to bridge the gap in cancer care disparities
Healthcare | February 07, 2024

American Cancer Society and Pfizer announce a US $15 million initiative to bridge the gap in cancer care disparities

The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support


IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
News | February 07, 2024

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM


Dr. Jitendra Singh launches multi-disciplinary post-doctoral courses in Bio-Sciences
News | February 06, 2024

Dr. Jitendra Singh launches multi-disciplinary post-doctoral courses in Bio-Sciences

1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector


Mandaviya inaugurates 24 health infrastructure facilities across AIIMS
News | February 05, 2024

Mandaviya inaugurates 24 health infrastructure facilities across AIIMS

Delivers keynote address at the 4th convocation of AIIMS Jodhpur


DPIIT recognises 1, 17,254 startups as on Dec 2023
Startup | February 03, 2024

DPIIT recognises 1, 17,254 startups as on Dec 2023

At least one recognised startup in every State and UT; spread across over 80% of districts


Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr
News | February 02, 2024

Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr

Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023


Glenmark partners Pfizer to launch Abrocitinib in India
Drug Approval | February 01, 2024

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India


AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
Clinical Trials | January 31, 2024

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation